Electrofusion Generates Diverse DC-tumour Cell Hybrids for Cancer Immunotherapy

Anticancer Research

Volumn 24, Issue 2 B, 2004, Pages 929-934

  Weise, Jan B ^a   Hilpert, Felix ^a   Heiser, Axel ^a   Görögh, Tibor ^a   Meyer, Jens E ^a   Weimer, Joerg ^a   Krüger, Christoph ^a   Rosenau, Andreas ^a   Wieckhorst, Wilm ^a   Arnold, Norbert ^a   Pfisterer, Jacobus ^a   Kabelitz, Dietrich ^a   Maune, Steffen ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Cancer; Dendritic cells; Electrofusion; Immunotherapy; Vaccine

Indexed keywords

ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL VIABILITY; DENDRITIC CELL; ELECTROFUSION (CELL); FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HYBRID CELL; PRIORITY JOURNAL; VACCINE PRODUCTION;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL FUSION; DENDRITIC CELLS; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; HYBRID CELLS; IMMUNOTHERAPY, ADOPTIVE; LARYNGEAL NEOPLASMS;

EID: 2442547693     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Heiser A, Coleman D, Dannull J et al: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumours. J Clin Invest 109(3): 409-417, 2002.
2. Houghton AN: Cancer antigens: immune recognition of self and altered self. J Exp Med 180: 1-4, 1994.
3. Boon T and van der Bruggen P: Human tumour antigen recognised by T lymphocytes. J Exp Med 183: 725-729, 1996.
4. Baratin M, Kayibanda M, Ziol M et al: Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope. J Pept Sci 8(7): 327-334, 2002.
5. Bronte V: Genetic vaccination for the active immunotherapy of cancer. Curr Gene Ther 1(1): 53-100, 2001.
6. Fukao T: Dendritic-cell-based anticancer vaccination: has it matured? Trends Immunol 23(5): 231-232, 2002.
7. Paludan C, Bickham K, Nikiforow S et al: Epstein-Barr nuclear antigen 1-specific CD4(+) Thl cells kill Burkitt's lymphoma cells. J Immunol 169: 1593-1603. 2002.
8. Ueno A, Arakawa F, Abe H et al: T-cell immunotherapy for human MK-l-expressing tumours using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Anticancer Res 22: 769-776, 2002.
9. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296, 1991.
10. Steinman RM: Dendritic cells and immune-based therapies. Exp Hematol 24: 859-862, 1996.
11. Guo Y, Wu M, Chen H et al: Effective tumour vaccine generated by fusion of hepatoma cells with activated B cells. Science 263: 518-520, 1994.
12. Orentas RJ, Schauer D, Bin Q et al: Electrofusion of a weekly immunogenic neuroblastoma with dendritic cells produces a tumour vaccine. Cell Immunol 213: 4-13, 2001.
13. Hui SW and Stenger DA: Electrofusion of cells: hybridoma production by electrofusion and polyethylene glycol. Cell Immunol 220: 212-227, 1993.
14. Ohnishi K, Chiba J, Goto Y et al: Improvement in the basic technology of electrofusion for generation of antibody-producing hybridomas. J Immunol Methods 100: 181-189, 1987.
15. Feuerstein B, Berger TG and Maczek C: A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods 245: 15-29, 2000.
16. Elomaa L, Joensuu H, Kulmala J et al: Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer. Acta Otolaryngol 115: 340-344, 1995.
17. Holtmeier C, Görögh T, Beier U et al: Overexpression of a novel lysyl oxidase-like gene in human head and neck squamous cell carcinomas. Anticancer Res 23: 2585-2592; 2003.
18. Russel WC, Newmann C and Williamson DH: A simple technique for demonstration of DNA in cells infected with mycoplasma and viruses. Nature 253: 461-462, 1975.
19. Trefzer U, Weingart G, Chen Y et al: A phase I trial with a hybrid cell vaccine in patients with metastatic melanoma. Adv Exp Med Biol 451: 519-525, 1998.
20. Stuhler G and Walden P: Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes. Cancer Immunol Immunother 39: 342-345, 1994.
21. Scott-Taylor TH, Pettengell R, Clarke I et al: Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 1500: 265-279, 2000.
22. Nair SK, Morse M, Boczkowski D et al: Induction of tumour specific cytotoxic T lymphocytes in cancer patients by autologous tumour RNA-transfected dendritic cells. Ann Surg 235: 540-549, 2002.
23. Nestle FO, Alijagic S, Gilliet M et al: Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
24. Hsu FJ, Benike C, Fagnoni F et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58, 1996.
25. Parkhurst MR, DePan C, Riley JP et al: Hybrids of dendritic cells and tumour cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumour-associated antigens in the context of MHC class I and class II molecules. J Immunol 170: 5317-5325, 2003.
26. Gottfried E, Krieg R, Eichelberg C et al: Characterization of cells prepared by dendritic cell-tumour cell fusion. Cancer Immun 2: 15, 2002.
27. Siders WM, Vergilis KL, Johnson C et al: Induction of specific antitumour immunity in the mouse with the electrofusion product of tumour cells and dendritic cells. Mol Ther 7: 498-505, 2003.
28. Phan V, Errington F, Cheong SC et al: A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumour cell hybrid vaccines. Nat Med 9: 1215-1219, 2003.
29. Banchereau J, Schuler-Thurner B, Palucka AK et al: Dendritic cells as vectors for therapy. Cell 106: 271-274, 2001.
30. Gong J, Chen D, Kashiwaba M et al: Induction of antitumour activity by immunization with fusions of dendritic and carinoma cells. Nat Med 3: 558-561, 1997.
31. Murphy G, Tjoa B, Ragde H et al: Phase I clinical trial T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A201-specific peptides from prostate specific membrane antigen. Prostate 29: 371-380, 1996.
32. Tjoa BA, Erikson SL, Bowes VA et al: Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32: 272-278, 1997.
33. Krause SW, Neumann C, Soruri A et al: The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumour cells and dendritic cells. J Immunother 25: 421-428, 2002.
34. Kikuchi T, Akasaki Y, Irie M et al: Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50: 337-344, 2001.
35. Zimmerman U: Electric field-mediated fusion and related electrical phenomena. Biochim Biophys Acta 694: 227-277, 1982.
36. Sowers AE: The study of membrane fusion and electroporation mechanisms. In: Charge and Field Ejects in Biosystems (Allem MJ, Cleary SF, Hawkridge FM, eds). New York, Plenum Press 1989, pp 315-337.
37. Zhelev DV, Dimitrov DS and Dionov P: Correlation between physical parameters in electrofusion and electroporation of protoplasts. Bioelectroch Bioener 20: 155-167, 1988.
38. Benz R and Zimmermann U: The resealing process of lipid bilayers after reversible electrical breakdown. Biochem Biophys Acta 640: 169-178, 1981.